Project Grant HT9425261E283
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $865,284 Project Grant award dated August 15, 2026, from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The award supports a four-year research initiative titled "Biochemical and Structural Targeting of the GAQ-Mutant Melanoma Subtype," with completion scheduled for August 14, 2030. This project conducts advanced biomedical research...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $878,043 project grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the project titled "Biochemical and Structural Targeting of the GAQ-Mutant Melanoma Subtype." The four-year award, effective August 15, 2026, through August 14, 2030, supports hypothesis-driven biomedical research aimed at developing innovative...
- This federal Project Grant award of $1,041,595.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF) on September 1, 2024. The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, this 3-year Melanoma Research Program Team Science Award will fund innovative and...
- The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1,620,505 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026, through May 31, 2029. The award funds research and development services focused on "Novel Mitochondrial Metabolism Inhibitors for Aggressive and Treatment-Resistant MYC-High Breast Cancers," with research activities conducted at...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1.4 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026, through July 31, 2029. The award funds research investigating metabolic mechanisms of resistance to mutant isocitrate dehydrogenase (IDH) inhibition in gliomas, with work performed at UCSF's San Francisco campus. This three-year research...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1.148M Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2028. This award supports research focused on targeting and imaging vitamin B5 metabolism in diffuse midline gliomas—a critical oncology research initiative addressing advanced biomedical challenges relevant to military health...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1.97M Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports the development of CD46-targeted antibody fragment radiopharmaceutical therapy for prostate cancer treatment. This research initiative represents a translational medicine effort to advance diagnostic and...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1,226,730 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2029. The award funds research investigating the canonical Polycomb Repressive Complex 1 (cPRC1) as an intrinsic mechanism of resistance to enzalutamide in advanced prostate cancer. This hypothesis-driven research initiative...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $328,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2025, through June 30, 2027. The award funds research on intracranial drug delivery strategies targeting skull bone marrow to generate antitumoral myeloid cell immune responses against glioblastoma. This research initiative represents UCSF's...
The University of California, San Francisco (UCSF) received a $1,054,812 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective August 15, 2026, through August 14, 2030. The grant funds research focused on "Biochemical and Structural Targeting of the GAQ-Mutant Melanoma Subtype," with performance conducted at UCSF's San Francisco, California facility. Under this award, UCSF will deliver basic and applied biomedical research services directed at developing therapeutic solutions and advancing scientific understanding of this specific melanoma variant, addressing a priority within the Defense Health Agency's broader portfolio of medical research initiatives. The Military Medical Research and Development program supports hypothesis-driven research designed to transform healthcare for military service members and the American public through innovative medical solutions. Within this framework, UCSF's melanoma research project contributes to the program's emphasis on oncology and precision medicine, leveraging the institution's established capabilities in cancer research and translational medicine. The four-year performance period aligns with typical award durations under this assistance listing, which generally ranges from three to four years.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.1m | 6/10/26 |